An Open Label PET Imaging Study to Evaluate the mGlu5 Receptor Occupancy Following ADX48621 (Dipraglurant) Administration

Trial Profile

An Open Label PET Imaging Study to Evaluate the mGlu5 Receptor Occupancy Following ADX48621 (Dipraglurant) Administration

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs Dipraglurant (Primary)
  • Indications Drug-induced dyskinesia; Dystonia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 03 Mar 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 03 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 13 Sep 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top